Humira's approval widened to include ulcerative colitis

Humira's approval widened to include ulcerative colitis

(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.

Humira—an anti- agent that's designed to suppress abnormal inflammatory and immune responses—has already been approved to treat a host of conditions, including , Crohn's disease, and plaque psoriasis.

Ulcerative colitis affects about 620,000 people in the United States, according to the U.S. National Institutes of Health.

The most common side effects of Humira include infection, injection-site reaction, headache, and rash, according to an FDA news release.

The drug is manufactured by Abbott Laboratories, based in North Chicago, Ill.

More information: The U.S. National Library of Medicine has more about ulcerative colitis.

add to favorites email to friend print save as pdf

Related Stories

Pfizer says patient died in oral RA drug study

Apr 22, 2011

(AP) -- Pfizer Inc. confirmed that one patient who was taking its drug candidate tofacitinib, a pill designed to treat rheumatoid arthritis, died during a recent clinical trial and said the death was connected to the drug.

FDA: Arthritis drugs pose cancer risk to children

Aug 04, 2009

(AP) -- Federal regulators on Tuesday added stronger warnings to a group of best-selling drugs used to treat arthritis and other inflammatory diseases, saying they can increase the risk of cancer in children and adolescents.

Marqibo approved for ph- acute lymphoblastic leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Recommended for you

Journal raises concern about blood-thinning drug

11 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

User comments